Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the findings of a Phase I study of olverembatinib in patients with relapsed/refractory (R/R) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL; NCT04260022). Overall, olverembatinib showed high efficacy and good tolerability in heavily pre-treated patients, including those that had T315I mutations or who were resistant to ponatinib and asciminib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
